Adenovirus mediated alpha interferon (IFN-alpha) gene transfer into CD34(+) cells and CML mononuclear cells

被引:23
作者
Feldman, E
Ahmed, T
Lutton, JD
Farley, T
Tani, K
Freund, M
Asano, S
Abraham, NG
机构
[1] NEW YORK MED COLL,DEPT PHARMACOL,VALHALLA,NY 10595
[2] NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595
[3] UNIV TOKYO,INST MED SCI,TOKYO,JAPAN
[4] UNIV ROSTOCK,DIV HEMATOL & ONCOL,ROSTOCK,GERMANY
关键词
D O I
10.1002/stem.150386
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Gene transfer or gene therapy has advantages in the treatment of a variety of disorders due to its selective expression within specific mammalian cells. Interferon-alpha (IFN-alpha) has been used in the management of leukemia but its diverse adverse activities with multiple potential side effects, possibly unrelated to therapeutic targets, may negatively influence the ability of IFN-alpha to treat this disorder. Therefore, we examined the ability of adenovirus (Ad)-IFN-alpha gene construct to transfect normal (CD34(+) cells) and chronic myelogenous leukemia (CML) bone marrow mononuclear cells (BMMNC) and the transient overexpression of IFN-alpha in these cells. Ad-cytomegalovirus promoter driven IFN-alpha (AdCMV-IFN-alpha) at multiple doses was assessed to transfect highly purified CD34(+) cells in liquid culture, and optimal transduction of CD34(+) cells was achieved using 120 plaque forming units. Flow cytometric determinations revealed that there was no significant difference in cell viability for the 4 h or 24 h transfection periods. Immunoassay of IFN-alpha produced by CD34(+) cells shows that IFN-alpha levels increased several fold in transfected cells. Transient expression of the IFN-alpha gene did not suppress proliferation of CD34(+) progenitors as indicated by BFU-E or colony forming units-granulocyte-macrophage (CPU-GM) growth. Reverse transcriptase/polymerase chain reaction analysis of RNA from CD34(+) harvested CFU-GM progenitor cells demonstrated transient IFN-alpha mRNA expression. Similarly, CML BMMNC were transfected with AdCMV-IFN-alpha under similar conditions as described for CD34(+) cells. BMMNC cells exposed to adenovirus for 24 h and 48 h were found to express IFN-alpha at a substantial level. This in vitro data suggest that Ad-mediated gene transfer of IFN-alpha into hematopoietic stem cells can be achieved and that the IFN-alpha gene can be translated into its specific mRNA in CD34 progenitor cells.
引用
收藏
页码:386 / 395
页数:10
相关论文
共 46 条
[1]  
ABRAHAM NG, 1995, INVEST OPHTH VIS SCI, V36, P2202
[2]   REGULATION OF CYTOKINE EXPRESSION BY INTERFERON-ALPHA IN HUMAN BONE-MARROW STROMAL CELLS - INHIBITION OF HEMATOPOIETIC GROWTH-FACTORS AND INDUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
AMAN, MJ ;
KELLER, U ;
DERIGS, G ;
MOHAMADZADEH, M ;
HUBER, C ;
PESCHEL, C .
BLOOD, 1994, 84 (12) :4142-4150
[3]  
AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P121
[4]   ANTIGEN CD34+ MARROW-CELLS ENGRAFT LETHALLY IRRADIATED BABOONS [J].
BERENSON, RJ ;
ANDREWS, RG ;
BENSINGER, WI ;
KALAMASZ, D ;
KNITTER, G ;
BUCKNER, CD ;
BERNSTEIN, ID .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (03) :951-955
[5]   ABNORMAL FUNCTION OF THE BONE-MARROW MICROENVIRONMENT IN CHRONIC MYELOGENOUS LEUKEMIA - ROLE OF MALIGNANT STROMAL MACROPHAGES [J].
BHATIA, R ;
MCGLAVE, PB ;
DEWALD, GW ;
BLAZAR, BR ;
VERFAILLIE, CM .
BLOOD, 1995, 85 (12) :3636-3645
[6]   Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia [J].
Bhatia, R ;
McCarthy, JB ;
Verfaillie, CM .
BLOOD, 1996, 87 (09) :3883-3891
[7]   TREATMENT OF MARROW STROMA WITH INTERFERON-ALPHA RESTORES NORMAL BETA-1 INTEGRIN-DEPENDENT ADHESION OF CHRONIC MYELOGENOUS LEUKEMIA HEMATOPOIETIC PROGENITORS - ROLE OF MIP-1-ALPHA [J].
BHATIA, R ;
MCGLAVE, PB ;
VERFAILLIE, CM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :931-939
[8]  
BHATIA R, 1994, EXP HEMATOL, V22, pA797
[9]   CYTOKINE-DEPENDENT LONG-TERM CULTURE OF HIGHLY ENRICHED PRECURSORS OF HEMATOPOIETIC PROGENITOR CELLS FROM HUMAN BONE-MARROW [J].
BRANDT, J ;
SROUR, EF ;
VANBESIEN, K ;
BRIDDELL, RA ;
HOFFMAN, R .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03) :932-941
[10]  
BROXMEYER HE, 1983, J IMMUNOL, V131, P1330